BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, February 17, 2025
Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review
See today's BioWorld Science
Home
» CLDN1 is a therapeutic target in primary sclerosing cholangitis
To read the full story,
subscribe
or
sign in
.
Gastrointestinal
CLDN1 is a therapeutic target in primary sclerosing cholangitis
Nov. 22, 2022
No Comments
Primary sclerosing cholangitis (PSC) is a disease affecting the bile ducts that can lead to end-stage liver disease and cholangiocarcinoma. Patients with this disease lack therapeutic treatment other than liver transplantation.
BioWorld Science
Conferences
Targeted therapy
Gastrointestinal